Author(s): Hankey GJ, Eikelboom JW
Abstract Share this page
Abstract For more than 20 years, moderately raised concentrations of total homocysteine (tHcy) have been associated with an increased risk of atherothrombotic vascular events but only recently has evidence mounted to suggest that the association may be causal. The association is independent of other factors, it is fairly consistent across many studies, it is strong and dose-related, and it is biologically plausible. However, the evidence needs to be strengthened by a systematic review of all comparable studies and the demonstration, in randomised trials, that lowering tHcy is followed by a significant reduction in atherothrombotic vascular disease. In addition, the measurement of tHcy needs to be standardised. If these can be achieved then tHcy measurement will become another useful marker of vascular risk, multivitamin therapy will be another therapeutic option for people at risk of atherothrombotic vascular disease, and fortification of food with folic acid will rise high on the political and public health agenda.
This article was published in Lancet
and referenced in Journal of Vascular Medicine & Surgery
- Ishfaq A Bukhari
Protective Effect of Diltiazem and Fenofibrate Against Ischemia-reperfusion Induced Cardiac Arrhythmias in the Isolated Rat Heart.
PPT Version | PDF Version
- Antonio Ferrari
Spontaneous Ventricular Arrhythmias in Early Clinical Trials A Report from a Single and Repeated Ascending Dose Study
- Mohamed Chahine
A novel mechanism of an SCN5A mutation causing mixed arrhythmias associated with dilated cardiomyopathy
- Saverio Gentile
Ion channels phosphorylopathy: 3rd International Conference on Clinical & Experimental Cardiology April 15-17, 2013 A link between genomic variations and heart arrhythmia